December 18, 2020


Covax vaccine deals – Low-income countries have long been counting on the $AZN-Oxford vaccine. Today, the COVAX program to secure access for poor countries announced another deal: an advance purchase agreement with AstraZeneca for 170 million doses.

COVAX Announces additional deals to access promising COVID-19 vaccine candidates; plans global rollout starting Q1 2021

The new deals involve vaccines that are still being studied for effectiveness and safety, one made by AstraZeneca and the University of Oxford and another by Johnson & Johnson. While discussions have been underway, no arrangements have yet been finalized to procure the FDA-approved BioNTech-Pfizer vaccine that is already being administered in countries including the United States and Britain.

continue reading

Leave a Reply